Coherus Oncology (CHRS) vs Satellos Bioscience (MSLE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Satellos Bioscience (MSLE) has outperformed Coherus Oncology (CHRS) over the past year, gaining 5.4% versus a loss of 40.9%. Over five years, MSLE leads with a -48.9% price change compared with -94.1% for CHRS. Satellos Bioscience is the larger company by market cap ($161.9 million vs $156.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CHRS | MSLE |
|---|---|---|
| Share price | $1.01 | $7.63 |
| Market cap | $156.05M | $161.88M |
| 1-day change | -1.94% | +1.19% |
| YTD return | -28.87% | +29.76% |
| 1-year return | -40.94% | +5.44% |
| 5-year return | -94.06% | -48.93% |
| EPS (TTM) | $-1.25 | $-1.94 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.62 | $13.40 |
| 52-week low | $1.01 | $5.30 |
| Distance from 52-week high | -61.39% | -43.04% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +667.33% | +244.04% |
| Average volume | 1.14M | 51.35K |
| Shares outstanding | 154.50M | 21.22M |
| Employees | 144 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MSLE has outperformed CHRS by 46.4 percentage points over the past year.
About Coherus Oncology
CHRS stock →Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees
About Satellos Bioscience
MSLE stock →Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo.
Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees
CHRS vs MSLE FAQ
Which is bigger, Coherus Oncology or Satellos Bioscience?
Satellos Bioscience (MSLE) is larger, with a market capitalization of $161.88M compared with $156.05M for Coherus Oncology (CHRS).
Which stock has performed better over the past year, CHRS or MSLE?
MSLE returned +5.44% over the past 12 months, compared with -40.94% for CHRS (price return, excluding dividends). Past performance does not predict future results.
Are Coherus Oncology and Satellos Bioscience in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Coherus Oncology and Biotechnology: Pharmaceutical Preparations for Satellos Bioscience.